Teclistamab plus daratumumab and hyaluronidase-fihj is approved for relapsed or refractory MM after one prior line of therapy, including a proteasome inhibitor and immunomodulatory agent.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/fda-approves-new-drug-combo-rr-multiple-myeloma-2026a10006xg?src=rss
Author :
Publish date : 2026-03-06 10:29:00
Copyright for syndicated content belongs to the linked Source.
